It is known that vitamin B12 inhibits the replication of HCV in vitro. Adding vitamin B12 to therapy with pegylated interferon and ribavirin in previously untreated patients is almost 2 times more likely caused by a viral response (72% treated with vitamin B12, and only 38% received only standard therapy), according to a published in the online edition of the journal Gut article Gerardo Nardon (Gerardo Nardone) and his colleagues at the University of Naples (University of Naples in Italy).
In addition, the viral response was observed more frequently in patients with the most resistant to the treatment of genotype 1 hepatitis C virus (HCV) and high viral load. Rapid viral response developed equally frequently in both groups, but significantly more often - in the vitamin B12 in patients with high initial viral load and genotype 1 HCV. In the group with standard therapy was not significantly more responders to treatment. The number of complications and side effects in both groups did not differ.
The researchers note that the cost of treating one patient with genotype 1 HCV exceed $ 15,000, but in their study, the frequency of viral replication in these patients was 41% rise in price during the treatment a little more than $ 20. However, they point out that these results should be interpreted with caution because the study was conducted in small groups of patients and without placebo control.
The importance of a safe, low-cost additional treatment for patients with HCV comes to the fore because of problems with new antiviral agents that are directly applicable to the virus.
"Antiviral drugs are a new generation require careful monitoring and strict application of rules to prevent the emergence of resistant strains of HCV and the development of an overdose patient" - the researchers said. Meanwhile, the standard therapy plus vitamin B12 may be useful for patients with stable chronic infections to treatment.
"This strategy would be especially useful in countries where, because of limited economic means a new generation of antiviral agents can not be applied in routine clinical practice" - the authors conclude.
In addition, the viral response was observed more frequently in patients with the most resistant to the treatment of genotype 1 hepatitis C virus (HCV) and high viral load. Rapid viral response developed equally frequently in both groups, but significantly more often - in the vitamin B12 in patients with high initial viral load and genotype 1 HCV. In the group with standard therapy was not significantly more responders to treatment. The number of complications and side effects in both groups did not differ.
The researchers note that the cost of treating one patient with genotype 1 HCV exceed $ 15,000, but in their study, the frequency of viral replication in these patients was 41% rise in price during the treatment a little more than $ 20. However, they point out that these results should be interpreted with caution because the study was conducted in small groups of patients and without placebo control.
The importance of a safe, low-cost additional treatment for patients with HCV comes to the fore because of problems with new antiviral agents that are directly applicable to the virus.
"Antiviral drugs are a new generation require careful monitoring and strict application of rules to prevent the emergence of resistant strains of HCV and the development of an overdose patient" - the researchers said. Meanwhile, the standard therapy plus vitamin B12 may be useful for patients with stable chronic infections to treatment.
"This strategy would be especially useful in countries where, because of limited economic means a new generation of antiviral agents can not be applied in routine clinical practice" - the authors conclude.
tags: med-news-pro.blogspot.com,
med-news-pro, med newspro, med-news blogspot
No comments:
Post a Comment